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Abstract
We describe the design and synthesis of a new Tc-99m labeled bioconjugate for imaging activated complement, based on
Short Consensus Repeats 1 and 2 of Complement Receptor 2 (CR2), the binding domain for C3d. To avoid non specific
modification of CR2 and the potential for modifying lysine residues critical to the CR2/C3d contact surface, we engineered a
new protein, recombinant CR2 (rCR2), to include the C-terminal sequence VFPLECHHHHHH, a hexahistidine tag (for site-
specific radiolabeling with [99mTc(CO)3(OH2)3]
+). The protein was characterized by N-terminal sequencing, SDS-PAGE and
size exclusion chromatography. To test the function of the recombinant CR2, binding to C3d was confirmed by enzyme-
linked immunosorbent assay (ELISA). The function was further confirmed by binding of rCR2 to C3d+ red blood cells (RBC)
which were generated by deposition of human or rat C3d and analyzed by fluorescence microscopy and flow cytometry.
The affinity of rCR2 for C3d+, in presence of 150 mM NaCl, was measured using surface plasma resonance giving rise to a
KD<500 nM. Radiolabeling of rCR2 or an inactive mutant of rCR2 (K41E CR2) or an unrelated protein of a similar size (C2A)
with [99mTc(CO)3(OH2)3]
+ at gave radiochemical yields .95%. Site-specifically radiolabeled rCR2 bound to C3d to C3d+ RBC.
Binding of radiolabeled rCR2 to C3d was inhibited by anti-C3d and the radiolabeled inactive mutant K41E CR2 and C2A did
not bind to C3d+ RBCs. We conclude that rCR2-Tc99m has excellent radiolabeling, stability and C3d binding characteristics
and warrants in vivo evaluation as an activated complement imaging agent.
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Introduction
Ischemia reperfusion injury (IRI) occurs when blood flow is
restored to tissue after a period of ischemia [1]. It is responsible for
much of the morbidity and mortality associated with conditions
such as myocardial infarction, stroke, gut ischemia, and cardio-
pulmonary bypass. Ischemia reperfusion damage of transplanted
organs such as kidney, heart, liver and lung also has a major
impact on graft survival [2,3,4]. The pathophysiology of IRI is
complex and consists of at least three major factors contributing to
tissue injury: reactive oxygen species (ROS), white blood cells
(neutrophils and macrophages), and components of the activated
complement (C) cascade [5,6,7].
We have previously shown that complement proteins, such as
C3, are synthesised by tissue parenchyma as an early response to
tissue stress or infection [8,9,10]. C3, whether synthesized locally
or deposited onto stressed cells by circulating C3, is cleaved on the
target cell surface to form the C3b fragment and then further
degraded into the membrane anchored C3dg and C3d fragments
which remain covalently bound to the cell. The products of
complement result not only in cell lysis but also opsonisation and
recruitment of inflammatory cells. Complement activation has
been described in the IRI of organs secondary to cardiovascular
disease and in transplantation and can involve all three known
pathways (the lectin (or mannose-binding) pathway, and the
alternative and classical pathways). C3d is therefore a ‘footprint’ of
complement activation. In several organ models of IRI, these
terminal components of C3, C3b and C3d, are associated with
tissue injury, and in transplanted organs with graft rejection
[11,12,13]. Both C3 and C3b have a relatively short half-life in
serum or on the membrane and C3b degrades within minutes on
the plasma membrane of the effected cell. Thereafter C3d is
relatively stable in situ [8]. Here we present the development of a
Single Photon Emission Computed Tomography (SPECT)
imaging agent that specifically binds to the degraded components
of activated bound complement, namely C3dg and C3d, on the
surface of affected cells. The endogenous human receptor of C3d
is complement receptor type 2 (CR2 or CD21), and is comprised
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of 16 short consensus repeats (SCRs). The first two N-terminal
domains, SCR1 and SCR2, are required for binding to C3d
[14,15] (Manuscript submitted, Supplemental Information). Here
we describe a 15.5 kDa SCR1/2 fragment (recombinant CR2 or
rCR2) which has been expressed, refolded and purified from E.
Coli. The recombinant CR2 was expressed with an additional C-
terminal histidine tag not only for ease of purification but also to
allow site specific labeling with technetium [99mTc(CO)3(OH2)3]
+.
When radiolabeling small proteins such as these, it is often
important to exert maximum control over the number and site of
modifications to the molecule. Until recently nearly all molecular
imaging studies have been performed using amine-reactive
bifunctional agents. Generally, modification of the e-amino groups
of lysine within a protein is used for conjugation of radioisotopes
via succinimide derivatives. Lysine modification has been the most
common method of conjugation, but due to its high abundance in
proteins there is an increased chance that a modification will occur
in the binding region of the agent and render it inactive. In most
cases the extent and statistical distribution of modification have
not been measured, and it has not been quantitatively demon-
strated that the bioconjugates retain full bioactivity compared with
unmodified protein. In cases such as these, the detrimental effects
are compounded because the lowest affinity (most heavily
modified) protein molecules carry a disproportionately high
radiolabel signal. Recently a study in which an anti-carcinoem-
brionic agent (CEA) diabody was labeled via lysines with N-
succinimidyl 4-[18F] fluorobenzoate which led to an immunore-
activity of only 57% [16]. For this to be translated into the clinic
the active agent would have to be purified to separate it from the
inactive agent. We also recently demonstrated that non-specific
‘‘amine-directed’’ labeling of a cell death SPECT imaging agent,
C2A (a domain of synaptotagmin I), led to abolition of binding to
its target, phosphatidylserine, while the inclusion of a novel site
specific C-terminal hexahistadine tag fully retained function [17].
Given these problems, producing recombinant protein conju-
gates to current good manufacturing practice (cGMP) standards
with consistent batch-to-batch quality using non-site-specific
modification for clinical imaging is problematic. Removal of any
inactive or low affinity protein prior to injection, if achievable at
all, requires additional affinity chromatography purification steps.
A cGMP recombinant protein imaging agent developed for
clinical application should be labeled site-specifically, reproduc-
ibly, efficiently and at room temperature. Preferably it should be a
simple kit-based method providing a well-characterized, homoge-
neous, fully functional and stable product.
With this in mind, we have genetically engineered rCR2 with a
C-terminal domain designed for site-specific modification with
maximum versatility, incorporating a HexaHistidine tag (His-tag).
Here, the term site-specific refers to the ability to radiolabel a
radiopharmaceutical via His-tag without interfering with its
function. The His-tag can be used not only for immobilized metal
affinity chromatography (IMAC) purification, but also in principle
for site-specifically labeling with 99mTc using [99mTc(CO)3(OH2)3]
+
[18]. The His-tag is non-immunogenic and does not hinder the
clinical development of His-tag -containing recombinant proteins
[19,20,21,22]. In this paper we report the use of this strategy to
develop a site-specific radiopharmaceutical for the imaging of
activated complement.
Materials and Methods
Molecular Biology
The recombinant Complement Receptor 2 (rCR2) gene was
designed using the amino acid residues 21–154 of human CR2
(Swiss-Prot accession: P20023 [23]) containing the Short Consensus
Repeats (SCR) one and two, the linker region between SCR two
and SCR three with the addition of a C-terminal tag including the
SCR2 to SCR3 linker (VFPLEC) and a hexahistidine tag. The
synthetic rCR2 DNA was codon optimized for bacterial expression,
synthesized, and sub-cloned into the pET-24a vector (Merck
Chemicals, UK) using the restriction enzymes NdeI and EcoRI,
by GeneArt (Regensburg, Germany). The rCR2 gene was
sequenced by King’s College London, Molecular Biology Unit, UK.
After sequence confirmation the rCR2 containing plasmid was
transformed into the BL21 (DE3) (Invitrogen, UK) strain of
Escherichia coli and selected on kanamycin (50 mg/mL) agar plates.
An individual colony was selected to inoculate a seed culture in
10 mL Luria Bertani (LB) media containing 50 mg/mL kanamycin
(Sigma, Gillingham, UK) and grown overnight at 37uC with
agitation. The seed culture was then used to inoculate 500 mL LB
media and grown at 37uC in baffled flasks with agitation until the
OD600 reached 0.7. Expression was then induced by addition of
1 mM isopropyl b-D-1-thiogalactopyranoside (IPTG) (Merck
Chemicals, Nottingham, UK) followed by further incubation at
37uC with agitation for 4 h. Cells were then pelleted by
centrifugation at 4,100 relative centrifugal force (RCF) for
10 min. and the cell pellets stored at 280uC. Frozen pellets were
thawed and resuspended in 20 mL sonication buffer, 50 mM Tris-
HCl (Fisher Scientific, Loughborough, UK ) pH 8.0, 150 mM
NaCl (Sigma, Gillingham, UK), 1 mM EDTA (Fisher Scientific,
Loughborough, UK), 0.1% TritonX-100 (Alfa Aesar, Heysham,
UK) and Complete Protease Inhibitors (Roche Diagnostic,
Burgess Hill, UK) and lysed via sonication at 60% amplitude on
ice for 5 bursts of 15 sec. with 30 sec intervals. The suspension was
then centrifuged at 4uC for 20 min. at 35,000 RCF.
A SDS PAGE gel was transferred onto PVDF membrane
(Invitrogen, UK) and the protein bands excised and analyzed via
N-terminal sequencing (Department of Biochemistry, University of
Cambridge).
A protein refolding procedure was adapted from the refolding of
SCR1–3 of the human CR1 [24]. Briefly, the insoluble fraction,
containing mostly inclusion bodies, was washed 3 times with 35 ml of
wash buffer (50 mMTris HCl pH 8.0, 1 mMEDTA, 50 mMNaCl,
complete protease inhibitors), resuspending the pellet and centrifu-
gation at 35,000 RCF for 20 min. The washed inclusion bodies were
then immediately solubilised by slowly adding 150 mL of solubilising
buffer (8 M urea, 20 mM Tris HCl pH 8.5, 1 mM EDTA, 5 mM
DTT, protease inhibitors, pH 8.5) while stirring. The solution was
then gently mixed at room temperature (RT) for 2 hrs. The inclusion
body solution was then slowly pumped at 1 mL/min. into 4 L of
refold buffer (300 mM ethanolamine (Sigma, Poole, UK), 1 mM
EDTA, 1 mM cysteine (Sigma, Poole, UK), 2 mM cystine (Sigma,
Poole, UK), protease inhibitors, pH 11, prepared the day before and
cooled to 4uC) while gently stirring. The sample was then stored at
4uC for 24 hours for refolding to occur. The 4 L of refold buffer
containing the rCR2 was concentrated to ,50 mL by ultrafiltration
using a Vivaflow 200 5 kDa membrane cutoff tangential flow
filtration system (Sartorius Stedim, Surrey, UK). The sample was
recirculated through the unit using a peristaltic pump at ,200 mL/
min., at a pressure of,2.5 bar. In preparation for immobilizedmetal
affinity chromatography, the protein was dialysed overnight into
nickel binding buffer (20 mM sodium phosphate pH 7.4, 0.5 M
NaCl, 40 mM Imidazole) After dialysis the solution was added to a
1 mL nickel column (GE Healthcare, Amersham, UK), which had
previously been equilibrated with nickel binding buffer, at 1 mL/
min. using an AKTA FPLC (GE Healthcare, Amersham, UK).
Impurities were washed with 100 mM imidazole and rCR2 was
eluted with 400 mM imidazole). 0.5 mL fractions were collected and
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analysed by SDS PAGE. 3 mL of eluate from the IMAC columnwas
then loaded on a Sephacryl 100 size exclusion column (60 cm height
and 2.6 cm diameter, GE Healthcare, Amersham, UK), which had
been equilibrated with size exclusion buffer (PBS pH 7.4 and 0.5 M
NaCl), at a flow rate of 1 mL/min. 1 mL fractions were collected
and analyzed by SDS PAGE.
The mutation of lysine 41 to glutamic acid in SCR 1 of CR2
(K41E CR2) has previously been shown to abrogate binding to
C3d. It was expressed, purified and characterised as previously
described (Manuscript submitted, Supplemental information).
rCR2 ELISA protocol
Measurement of rCR2 binding to human C3d was performed
according to a standardized ELISA protocol. 96-well ELISA plates
(Greiner-one high protein binding, Sigma UK) were coated with
C3d protein (Merck, Darmstadt, Germany) at increasing two fold
concentrations ranging from 1.5 to 1500 nM/well and incubated at
4uC overnight in PBS pH 7.4. Plates were then washed three times
with wash buffer (1% Tween-PBS, pH 7.4) and blocked at RT for
1 hr with blocking buffer (3% Bovine Serum Albumin (BSA, Sigma,
UK) in PBS pH 7.4). The plate was then washed 3 times with wash
buffer. rCR2, or C2A (domain A of synaptotagmin I [17]), which is
an irrelevant His-tagged protein of the same size, were diluted in
0.05% BSA-PBS pH 7.4, added to antigen coated wells in triplicate
at a fixed concentration of 1.5 mM per well, and incubated for 1 h.
at room temperature. The plate was washed three times with wash
buffer and plates were incubated with anti-His secondary antibody
(Quiagen,UK) at a dilution of 1:1000 in 0.05% BSA-PBS pH 7.4
for 1 h. This was followed by a further washing step and then
addition of the substrate o-phenylenediamine (OPD) at 1 mg/mL
and adding 2 ml of 30% H2O2. After 30 minutes the absorbance at
450 nm was read using a SPECTRAmax 340PC microplate reader
(Molecular Devices Co., Sunnyvale, CA). On each ELISA plate
three control wells were included in triplicate where no C3d, rCR2
or secondary antibody had been added. The assay was performed in
triplicate and at least 3 independent experiments were performed.
Surface Plasmon Resonance
Binding of rCR2 to C3d was carried out on a Biacore T100
system (GE, Healthcare, Amersham, UK) at 25uC, according to
the manufacturer’s guidelines. Recombinant CR2 was dialysed
into running buffer (0.01 M HEPES, pH 7.4, 0.15 M NaCl,
3 mM EDTA, 0.005% Tween 20). A C3d construct, engineered to
include a free exposed thiol group, was generated by reversing the
initial Cys17Ala mutation (corresponding to Cys1010 of full length
C3). The resulting protein was immobilized onto a CM5 sensor
chip by thiol coupling of the free Cys17 using a ligand thiol
coupling kit according to the manufacturer’s instructions (Biacore
AB). A flow rate of 30 ml/min. was used and the ligand contact
time was 60 seconds with a dissociation time of 1200 seconds.
Analyte (rCR2) concentrations were injected in duplicate,
involving a titration series of ‘‘low to high’’ analyte concentration
followed by a ‘‘high to low’’ series [25]. Buffer blanks were also
included in the titration series. A blank flow cell was used as a
control surface. SPR data was processed with the Biaevalution
software 3.1 (Biacore AB). Curve fitting and other analyses were
performed using MicroCal Origin v7 (OriginLab).
C3d+ Red blood Cell binding assay
To generate C3d positive red blood cells (C3d+ RBC) in the
absence of cell lysis, 16108 sensitized sheep RBC (Diamedix,
Rome, Italy) in 3 mL of gelatin veronal buffer (Sigma) were
treated with either 25 ml of rat C6 deficient serum (kindly provided
by Professor Frank Baas, University of Amsterdam, Netherlands)
or human C6 deficient serum (Sigma) for 30 min. at 37uC.
Confirmation of C3d deposition onto the RBC membrane was
confirmed by incubating C3d+ RBC with a primary anti-human
C3d at a dilution of 1:100 followed by a wash and incubation with
a secondary mouse anti-human-FITC at a dilution of 1:200. Cells
were then analysed by immunofluorescent microscopy (Olympus
Bx51, Southend-on-Sea, UK) on a glass cover slide and by flow
cytometry (FACScan, Becton Dickinson, Oxford UK). To test the
binding capability of rCR2 to native human C3d, 1.5 mM rCR2,
C2A or K41E CR2 were each incubated with 2.56107 C3d+
RBCs in 1.5 mL of PBS and 2 mM EDTA for 60 min. The cells
were then centrifuged at 360 RCF, washed 3 times with PBS and
then incubated with a secondary anti-HIS-FITC (Abcam, Cam-
bridge, UK). The assay was performed in triplicate and repeated
in three independent experiments. Cells were then analysed by
immunofluorescent microscopy and a flow cytometer. To control
for non-specific binding unstained cells and IgG1 K isotype
antibody (eBiosciences, Hatfield, UK) were also tested. To further
determine the specificity of rCR2 for C3d, 2.56107 C3d+ RBC
were pre-incubated with 10 mg/mL of anti-human C3d prior to
rCR2 and secondary anti-HIS-FITC incubation.
99mTc labeling of rCR2, K41E CR2 and C2A
99mTc pertechnetate eluted with saline from a Drytec gene-
rator (GE Healthcare, Amersham, UK) was converted to
[99mTc(CO)3(OH2)3]
+ using an adapted kit from Isolink kitH
(generously provided by Covidien, Petten, The Netherlands).
Quality control was carried out according to manufacturer’s
instructions using instant thin layer chromatography (ITLC) and
analysis with a gamma-ray TLC scanner (Lablogic, UK) and high
performance liquid chromatography (HPLC series 1200, Agilent,
UK) equipped with an in-line gamma detector (Lablogic, UK).
Proteins were labeled with 99mTc by incubating 100 mg of rCR2,
C2A or K41E CR2 in 100 mL of PBS pH 7.4 with an additional
350 mM NaCl and up to 1 GBq of [99mTc(CO)3(OH2)3]
+ in
100 mL at 37 Cu. Unless otherwise stated the labeling of all species
was performed at a specific activity of 4 MBq/mg. However, to
reproduce a high (clinically relevant) specific activity, rCR2 was
also labeled at 10 MBq/mg. Radiolabeling efficiency was deter-
mined by ITLC as described above and the radiolabeling
efficiency was calculated as a ratio of the radiolabeled protein
peak integral (Rf = 0) to the unincorporated [
99mTc(CO)3(OH2)3]
+
peak integral (Rf = 1.0).
Binding of 99mTc-rCR2 to C3d+ cells
Binding of 99mTc-rCR2, K41E 99mTc-rCR2 and 99mTc-C2A to
C3d was evaluated by a C3d+ red blood cell assay as described
above. In the C3d+ red blood cell assay, 2.56107 C3d+ RBCs and
C3d- RBCs were incubated with 99mTc-rCR2, K41E 99mTc-CR2,
99mTc-C2A or 10 mg/mL anti-human C3d followed by 99mTc-
rCR2. Cells were then centrifuged at 360 RCF and washed five
times with PBS. The percent of total radioactivity bound to C3d+
RBCs was determined as a ratio of radioactivity associated with
the cell pellet, as determined by gamma counting (Wallac, 1282
COMPUGAMMA, PerkinElmer, UK), vs. total radioactivity
added. The assay was performed in triplicate and repeated in
three independent experiments.
Binding of 99mTc-rCR2to C3d
Binding of 99mTc-rCR2 to C3d was evaluated by ELISA using a
similar protocol as described above. However, ELISA 12 well
strips (Greiner Bio-One Ltd, Stonehouse, UK) were used which
allowed for individual wells to be separated and gamma counted.
99mTc-rCR2 was incubated in triplicate and the bound 99mTc-
A Radiopharmaceutical for Activated Complement
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rCR2 was determined by gamma counting the individual ELISA
wells. The radioactive ELISA was repeated in three independent
experiments. The saturation binding data was analyzed with
nonlinear regression assuming the one site specific binding model
using the equation Y=Bmax*X/(Kd+X) using GraphPad Prism
(GraphPad Software Inc. San Diego, USA).
Serum stability
1 mg/mL rCR2 and K41E CR2 were labeled with 400 MBq
[99mTc(CO)3(OH2)3]
+ for 30 min. at 37uC with gentle shaking.
After purification on a vivaspin500 (MW 3000 kDa Sartorius,
UK), labeled rCR2 or K41E CR2 was added to human serum
(Sigma) at 1:10 v/v. As a control, labeled rCR2 or K41E CR2 was
also added to PBS at 1:10 v/v. The samples were then incubated
at 37uC. At 0.5, 1, 2, 4, 8 and 24 h. samples were taken and
analyzed by instant thin layer chromatography (ITLC) using a
mobile phase of methanol and 1% concentrated HCl. As a control
a separate ITLC of [99mTc(CO)3(OH2)3]
+ and [TcO4]
2 was
performed in the same mobile phase. ITLC were then monitored
using a radio TLC scanner (LabLogic, UK). Serum stability was
calculated as the area under the protein peak (Rf = 0) versus the
area under the curve of the remainder of the chromatogram
([99mTc(CO)3(OH2)3]
+ or [TcO4]
2 Rf=1.0).
Results
Cloning, preparation and characterization of rCR2
The first two short consensus repeats (SCR) of complement
receptor 2 (CR2) were cloned into the pET24a bacterial
expression vector with the addition of a C-terminal spacer and a
HexaHistidine tag (His-tag), forming the construct rCR2. After
induced expression in E. coli, rCR2 was isolated from the insoluble
fraction via an inclusion body preparation, solubilised and refolded
by high dilution method in a redox buffer. Recombinant CR2 was
purified first via IMAC and further purified by size exclusion
chromatography (Figure 1a). Recombinant CR2 eluted as a single
discrete peak with a retention time expected for a protein of
,16 kDa, with no significant evidence of aggregation or
dimerization. Recombinant CR2 was analyzed by reduced and
non-reduced SDS PAGE, giving rise to a single monomeric band
at the expected molecular size (Figure 1b). When samples were
stored for prolonged periods and exposed to air, the formation of a
dimer was apparent by SDS PAGE (data not shown). The final
protein product was analyzed by N-terminal sequencing of the first
ten amino acids, giving the expected sequence of ISCGSPPPIL.
Recombinant CR2 binds to immobilized C3d
In vitro binding of rCR2 to C3d was confirmed by ELISA and
binding to C3d+ RBCs which was confirmed by immunofluores-
cent microscopy and flow cytometry. An rCR2 ELISA was
developed to test binding to immobilized C3d. Human C3d was
plated at increasing concentrations and then incubated with rCR2
followed by incubation with anti-HIS-HRP and substrate. rCR2
bound to C3d and showed an EC50 (estimated concentration that
corresponds to 50% of the OD450 response range) of ,48.5 nM
(Figure 2). Recombinant CR2 did not bind to empty ELISA wells,
and anti-HIS-HRP did not bind to C3d, both were comparable to
background absorptions. An irrelevant His-tag protein of similar
Figure 1. Size exclusion, SDS/PAGE and ES-MS characterization of rCR2. (A) After expression and purification by IMAC, rCR2 was further
purified by preparative size exclusion chromatography. In the fast protein liquid chromatography (FPLC) size exclusion chromatogram shown, a
discrete single peak was observed with a retention time of 80 min. as expected for a globular ,15 kDa protein compared to molecular weight
standards (data not shown). (B) The single peak obtained from the preparative size exclusion chromatography was analyzed by non-reduced (NR) and
reduced (R) SDS/PAGE electrophoresis. In the SDS PAGE gel shown, a single band under both the non reduced and reduced conditions of ,15 kDa
was observed as compared to molecular weight markers (M). This indicates that rCR2 exists as a single species and no dimer is present.
doi:10.1371/journal.pone.0018275.g001
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molecular weight, C2A, was tested in the ELISA and showed no
significant binding to C3d.
To determine the binding affinity of rCR2 to C3d, surface plasmon
resonance (SPR) analysis was performed. To simulate native binding
conditions a C3d construct that possessed a cysteine residue at
position 17 was used. In native C3d is modified to produce a buried
thioester moiety with Gln20. The acyl-amidazole activated side chain
can then form a covalent bond with nucleophiles during C3d-antigen
interactions [26]. The free thiol of Cys17 was used to immobilize C3d
to the carboxymethylated surface of the SPR chip, ensuring an
oriented, homogeneous immobilized C3d, with its ligand binding site
exposed for interaction with CR2. The rCR2/C3d interaction
displays ‘‘fast-on/fast-off’’ kinetics, where the association phase
reaches equilibrium and the bound complex dissociates at least as
Figure 2. rCR2 binding to C3d as measured by ELISA. To determine the binding of rCR2 to C3d, the antigen C3d was coated on ELISA plates at
increasing two fold concentrations. The ELISA wells were then incubated with rCR2 (circles) and an irrelevant protein C2A (squares) followed by anti-
HIS HRP and o-phenylenediamine substrate. Control ELISA wells with no C3d antigen or no rCR2 or anti-HIS HRP alone gave optical densities similar
to background (data not shown). Error bars represent the standard deviation of the mean of the triplicate.
doi:10.1371/journal.pone.0018275.g002
Figure 3. Surface plasmon resonance of rCR2. (A) A representative SPR sensorgram of rCR2 binding to immobilized C3d. C3d was coupled to
the SPR sensor chip using the free thiol of the Cys17 residue. Binding was determined over a range of rCR2 concentrations; shown here, 78 (pink), 156
(orange), 313 (purple), 625 (blue), 1250 (green), 2500 (green), 5000 (red) and 10000 nM (black). (B) The binding affinity of rCR2 to C3d was determined
by plotting the binding response at equilibrium against the concentration of rCR2 and fitting a Langmuir binding isotherm.
doi:10.1371/journal.pone.0018275.g003
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fast as the time required to transfer new buffer into the SPR flowcell
(Figure 3a). ‘‘Fast-on/fast-off’’ kinetics makes equilibrium analysis
straightforward but prevents precise measurement of association and
dissociation rate constants.
The binding affinity was determined by plotting the binding
response at equilibrium against the concentration of rCR2 and
fitting a Langmuir binding isotherm (Figure 3b). The Langmuir
model assumes that both binding partners are homogenous, the
analyte is monovalent, and that all binding events are independent
[27].This analysis indicates a KD of 570630 nM and the observed
Bmax value is consistent with a 1:1 binding stoichiometry; these
binding characteristics, in the presence of 150 mM NaCl, are in
agreement with ones previously reported for this interaction [28].
The non-binding mutant K41E rCR2 has previously been tested
in this system and also showed no binding in the SPR experiment
(manuscript submitted).
The ability of rCR2 to bind to C3d was also monitored by the
incubation of rCR2 with sensitized sheep red blood cells which
had previously been treated with C6 deficient human or rat serum
to induce the deposition of human or rat C3d, respectively. The
confirmation of human C3d deposition was enabled by immuno-
fluorescent microcopy using an anti-human C3d antibody
(Figure 4b). The binding of rCR2 was confirmed by incubating
human or rat C3d+ RBCs with rCR2 followed by staining with
anti-HIS-FITC (Figure 4d and 4f). Specificity of rCR2 binding to
C3d was confirmed by the absence of the K41E CR2 mutant
binding to C3d+ RBCs (Data not shown).
Binding of rCR2 to C3d+ cells was also evaluated by flow
cytometry, whereby human C3d+ RBCs were generated by
exposing sensitized sheep red blood cells to C6 deficient human
sera. C3d deposition was confirmed by using an anti-human C3d
antibody followed by an anti-human FITC secondary. Specificity of
the antibody was confirmed using C3d2 RBCs and incubation with
secondary antibody alone (Figure 5a) which showed no binding to
RBCs. Confirmation of rCR2 binding to human C3d+ cells was
demonstrated by incubating the cells with rCR2 followed by
secondary anti-HIS-FITC (Figure 5b). As a control experiment an
irrelevant His-tag protein, C2A, was incubated with C3d+ RBCs
Figure 4. Immunofluorescent microscopy of rCR2 or anti-C3d bound to C3d+ red blood cells. Sensitised sheep red blood cells were
incubated with either human (panels a, b, c and d) or rat (panels e and f) C6 deficient serum to generate C3d plasma membrane deposition in the
absence of cell lysis. Cells were then incubated with either anti-human C3d followed by mouse anti-human-FITC secondary (panel b) or secondary
antibody only (panel a). C3d+ cells were also incubated with rCR2 followed by secondary anti-HIS-FITC (panel d and f) or secondary alone (panel c
and e).
doi:10.1371/journal.pone.0018275.g004
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followed by secondary anti-His-FITC and showed no binding to
C3d+ cells (Figure 5c). The specificity of the rCR2 was corroborated
by the absence of immunostaining following blockade of C3d with
anti-C3d blocking antibody(Figure 5d), secondary antibody only
and incubation with C3d- RBCs (Figure 5b), all which showed no
binding to RBCs. The specificity was further corroborated when
K41E CR2 mutant showed no binding to C3d+ RBCs.
Labeling of rCR2 and K41E CR2 with [99mTc(CO)3]
+
Recombinant CR2 and K41E CR2 mutant were labeled at
1 mg/mL by incubating [99mTc(CO)3(OH2)3]
+ with 100 mg of
protein at 37uC with gentle shaking for up to 120 min. Radio-
chemical yield was determined by ITLC (Figure 5a). A
radiochemical yield of .95% was achieved with 1 mg/mL of
rCR2 and K41E CR2 within 30 min at 37uC. Longer incubation
times did not significantly improve the radiochemical yield
(Figure 6b). When rCR2 was radiolabeled at higher and more
clinically relevant specific activities (i.e. 7 MBq/mg), at 37uC for
30 min., radiolabeling efficiency of 95% was achieved.
Recombinant 99mTc-CR2 binds to C3d
In vitro binding of 99mTc-rCR2 to C3d was confirmed by ELISA
and binding to C3d+ RBCs. The ELISA was used to test 99mTc-
rCR2 binding to immobilized C3d and demonstrated that 99mTc-
rCR2 bound to C3d but did not bind in the absence of C3d (data
not shown). Using a non linear regression model to fit the
saturation binding curve gave rise to a Bmax 92067 (SE 61143)
and a Kd= 25.47 nM (SE 61.48 nM) (Figure 7). Binding of
99mTc-rCR2 to C3d+ cells was also evaluated in a modified C3d
RBC assay as described above. Confirmation of 99mTc-rCR2
binding to human C3d+ cells was demonstrated by incubating the
C3d+ RBCs with 99mTc-rCR2 and measuring the radioactivity
associated with the cells (Figure 7). As control conditions 99mTc-
K41E CR2 and 99mTc-C2A were also incubated with C3d+ RBCs
and showed no binding to C3d+ cells (Figure 8). The specificity of
the 99mTc-rCR2 was further corroborated by the absence of
binding to C3d+ RBCs with C3d antibody inhibition (Figure 8).
Serum stability of 99mTc radiolabeled rCR2 and K41E CR2
The stabilities of rCR2-[99mTc(CO)3] and K41E CR2-
[99mTc(CO)3] during incubation in PBS or serum over 24 h were
determined using ITLC with gamma detection (Table 1). 99mTc-
rCR2, K41E 99mTc-CR2, [99mTcO4]
2 and [99mTc(CO)3(OH2)3]
+
were analyzed beforehand in order to determine their migration
on ITLC plates (data not shown). For both 99mTc-rCR2 and
K41E 99mTc-CR2 only one radioactive peak, with Rf = 0, was
Figure 5. Flow Cytometry of rCR2 or anti-C3d bound to C3d+ red blood cells. Sensitised sheep red blood cells were incubated with human
C6 deficient serum to generate C3d deposition on RBC in the absence of cell lysis. (A) To confirm C3d deposition, C3d+ RBC incubated with anti-
human C3d (black line) or isotype control (solid grey) followed by mouse anti-human-FITC secondary. (B) To demonstrate rCR2 binding to C3d, C3d+
RBC cells were incubated with rCR2 (black line) or an irrelevant His-tag protein, C2A, (solid grey) followed by secondary anti-HIS-FITC. (C) To further
demonstrate that the mutant K41E CR2 mutant did not bind to C3d, C3d+ RBC cells were incubated with rCR2 (black line) or K41E CR2 (solid grey)
followed by secondary anti-HIS-FITC. (D) To demonstrate that rCR2 specifically bound to C3d, C3d+ RBC cells were first incubated with the inhibitory
anti-human C3d prior to incubation with rCR2 and secondary anti-HIS-FITC (solid grey) or as positive control rCR2 and secondary anti-HIS-FITC alone
(black line).
doi:10.1371/journal.pone.0018275.g005
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observed for the duration of the stability study for both PBS and
serum (Table 1).
Discussion
Numerous human and animal studies have affirmed the link
between IRI, complement activation and tissue damage, for
example in myocardial infarction. Therapeutic agents that target
C3 activation have reduced infarct size in animal models [29,30].
In transplantation, IRI is unavoidable, especially when cadaveric
donor organs are used. Greater IRI in cadaveric transplantation
compared to living donors is believed to contribute to an increased
incidence of delayed graft function (where dialysis is required for a
period post transplantation) from 5% to 25% [31,32]. A
correlation between delayed graft function, increased rates of
rejection and reduced long term graft survival and the length of
the cold ischaemia time has also been established [2].
To our knowledge this is the first description of a radiolabeled
imaging agent for the potential imaging of activated complement
post ischemia reperfusion injury. Currently no techniques exist to
non-invasively assess the degree of tissue injury within an affected
organ soon after IRI. Most existing imaging techniques rely on
functional or anatomical measurements such as organ perfusion or
scar formation, respectively. These measurements are often done
several days or even months post IRI and have little or no
prognostic value. For example, the prevention of left ventricular
(LV) dysfunction post-acute myocardial infarction (AMI) is
currently addressed in the European Society of Cardiology and
the European Association for Cardio-Thoracic Surgery guidelines
by focusing on minimal treatment delays, aggressive reperfusion
therapy, and the use of early and consistent optimal pharmaco-
logical therapy [33]. Recently, the MISSION! AMI clinical study
[34] demonstrated that the highest incidence of arrhythmic death
in post-AMI patients happens in the first three months after
discharge in patients with normal LV ejection fraction who are
thus considered at low risk. Several techniques have been
proposed to stratify patients and indentify those with higher risk
of sudden death following AMI. However, these techniques
Figure 6. Radiolabeling of rCR2. (A) rCR2 was incubated with [99mTc(CO)3(OH2)3]+ at 37uC for 30 minutes at a protein concentration of 1 mg/mL
and analysed by instant thin layer chromatography (ITLC). The radiolabeling efficiency was calculated as a ratio of the radiolabeled protein peak
integral (Rf = 0) to the unincorporated [
99mTc(CO)3(OH2)3]
+ peak integral (Rf = 1.0). (B) The radiolabeling efficiency was followed over a 120 minute
period. Aliquots were removed periodically and analysed by ITLC and the radiolabeling efficiency was determined over time.
doi:10.1371/journal.pone.0018275.g006
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offered limited additional information and have a low positive
predictive value (,30%) [34]. New methods are needed to solve
the important unmet need of correct identification of high risk
patients. One key aspect missing is a patho-physiological
measurement of the injured tissue post IRI. Ideally a biomarker
which can delineate the area at risk and the border zone around
necrotic tissue soon after IRI, which also remains for several days,
would be a powerful tool in risk stratification and guiding
intervention. One potential biomarker which may meet these
criteria is the activated complement molecule C3d. C3 is expressed
in the local micro environment of stressed tissue soon after IRI
which leads to the deposition of C3d on the plasma membrane of
affected cells and can remain for several days.
To non-invasively evaluate C3d post IRI we engineered a
recombinant complement receptor 2 with a C-terminal tag
(VFPLECHHHHHH) designed for site-specific labeling with
[99mTc(CO)3]
+. Under mild radiolabeling conditions (37uC for
30 min.), radiochemical yields exceeded 95% with a high specific
activity of 10 MBq/ug. Therefore, with further optimization a
simple kit-based labeling method could be developed without need
for post-labeling purification. We previously reported that the
addition of a CKLAAALEHHHHHH tag to the C-terminus of
the phosphatidylserine (PS)-binding domain of synaptotagmin I
(C2AcH), a cell death imaging agent, represented the first use of a
combination of a His-tag and a free cysteine residue as a tag for
incorporation of imaging probes into recombinant proteins.
Although it was designed for versatility, to allow the incorporation
of both a 99mTc radiolabel via the His-tag and other imaging
probes via covalent modification of the Cys, an unexpected benefit
was dramatic increase in the efficiency of labeling with
[99mTc(CO)3]
+, giving higher labeling yield and specific activity
under mild conditions, compared with C2A with His-tag
alone[17]. However for rCR2 we did not engineer a molecule
without the C-terminal free Cys and so in this case we did not
demonstrate that the combination of the Cys with the His-tag is
responsible for the high radiochemical yield and high specific
activity. Other groups have overcome this and shown that higher
temperatures and/or longer incubation times are required to
achieve adequate radiochemical yields with His-tagged proteins
[18].
Recombinant human CR2 bound with high affinity
(Kd= 500 nM) to human C3d enabling the detection of human
and rat C3d deposited onto sheep RBC. The inactive K41E
mutant of rCR2 did not bind to C3d and binding of rCR2 to
human C3d was inhibited by anti-human C3d. We were also able
Figure 7. 99mTc-rCR2 binds to C3d. To determine the binding of
99mTc-rCR2 to C3d, C3d antigen was coated on ELISA plates at
increasing two fold concentrations. The ELISA wells were then
incubated with rCR2. The supernatant was removed and after washing
the individual ELISA wells were gamma counted. The saturation binding
data was analysed using a non linear regression model assuming a one
site specific binding using the equation Y= Bmax*X/(Kd+X). Error bars
represent the standard error of the mean of the triplicate.
doi:10.1371/journal.pone.0018275.g007
Figure 8. 99mTc-rCR2 binds to C3d+ RBC. Sensitised sheep red blood cells were incubated with human C6 deficient serum to generate C3d
deposition on RBC in the absence of cell lysis. 99mTc-rCR2 , 99mTc-C2A or K41E 99mTc-rCR2 were added to 2.56107 C3d+ cells. The percentage
radioactivity bound to C3d+ cells was determined by gamma counting the activity associated with the cell pellet as percentage of total activity added.
Error bars represent the standard error of the mean of n = 5.
doi:10.1371/journal.pone.0018275.g008
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to demonstrate that the Techenitum-99m radiolabeled rCR2
bound specifically to C3d+ RBCs. This binding was inhibited by
anti-C3d. The inactive mutant K41E CR2 and the irrelevant
protein C2A radiolabeled comparably to rCR2 but did not bind to
C3d. It is of particular importance in this case not to have used an
‘‘amine directed’’ non-specific bifunctional chelator for radiola-
beling rCR2, as there is a greater likelihood of modifying Lysine
residue 41 in CR2 and rendering it unable to bind to C3d. Such
an approach was recently used to non-specifically cross link
recombinant CR2 fragment to superparamagnetic iron oxide
(SPIO) nanoparticles to generate targeted MR contrast agent for
imaging renal inflammation [35]. The affinity of 99mTc-CR2 was
also measure by ELISA and gave rise to Kd of ,25 nM. This
affinity is lower than observed by surface plasma resonance and be
due to using different binding buffers. It has previously been
reported that the binding of CR2 to C3d is dependent on the
buffer salt concentration [28].
In conclusion, we have developed and characterized a new and
versatile radiopharmaceutical for the potential of imaging
activated complement, based on rCR2, which contains the C3d
binding domain of complement receptor 2. It site-specifically
incorporates [99mTc(CO)3]
+ with excellent efficiency and is stable
in serum. The new site-specifically labeled rCR2-99mTc has
excellent affinity for C3d, and warrants in vivo evaluation for
imaging activated complement post ischemia reperfusion injury in
cardiovascular and graft rejection preclinical models.
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